3D Printing Brings Scaleability to Thermosets

 

Car doors, boats, pools, aerospace equipment…What do all of these products have in common?—They’re all made of thermosets. However, both thermoset products and thermoset tools were often limited in their production speed and efficiency due to their manufacturing method.

On today’s Engineering & Construction Podcast we explored thermosets, what they are, how they are made, modern-day uses, and the manufacturing process. Joining us on the podcast to unpack the industry of thermosets are Magnum Venus Products experts Mike Kastura, Senior Product Manager, and Hannah Jay, Jr. Marketing Manager.

Hannah Jay saidThermosets, thermoplastics? What is the difference? Mike and Hannah carefully explain the crucial difference between the composites, and why thermosets make a stronger, more durable product. But, thermosets have lagged behind thermoplastics in their ability to be scaled up in production. This is where Magnum Venus Products has upset the status quo and created something the industry didn’t even know it needed.

“We as consumers don’t know what we want,” Kastura said, quoting the famous Henry Ford—“‘If I had asked people what they wanted, they would have said faster horses.’”

Having a way to efficiently and economically produce thermosets can be incredibly useful to a variety of industries. And, as Jay chimed in, there is “substantial energy savings in thermoset processing.”

Magnum Venus Products is changing the narrative of the benefits of thermosets vs additive manufacturing by bring Reactive Additive Manufacturing to life, which will finally allow for the 3D printing of thermoset materials.

“Industry is demanding more efficient solutions,” Jay said. On this podcast we discovered how Magnum Venus Products is leading innovation and altering expectations in the field of temperature tolerant compounds.

For the latest news, videos, and podcasts in the Engineering & Construction Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More